Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2022-10-28 Director's Dealing
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
PDMR Dealing
Director's Dealing Classification · 100% confidence The document is an official notification of a share purchase by a Person Discharging Managerial Responsibilities (PDMR), specifically the Chief Financial Officer of Ondine Biomedical Inc. It includes detailed transaction data such as price, volume, date, and the identity of the individual, which is standard for a Director's Dealing report under UK Market Abuse Regulations.
2022-10-28 English
Ondine presents new efficacy data against MRSA
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's 'Reach' service. It announces new research findings regarding the company's photodisinfection technology presented at a conference. It does not fit into specific financial reporting categories like 10-K, IR, or ER, and it is not a report publication announcement (RPA) as it describes the research findings directly rather than just announcing the availability of a report. Therefore, it falls under the fallback category for general regulatory/corporate announcements.
2022-10-19 English
Steriwave™ cuts SSI risk by 47% at major hospital
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Ondine Biomedical Inc. regarding the results of a clinical study on their Steriwave product. It provides a summary of research findings presented at a conference and includes a link to download the full research poster. Since it is a general regulatory announcement regarding company news/research and does not fit into specific categories like financial reports or board changes, it is classified as a Regulatory Filing (RNS).
2022-10-19 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document is an announcement regarding an upcoming investor presentation. It provides details on how to register for the event and the date/time of the presentation, rather than being the presentation slides themselves. Following the 'Menu vs Meal' rule, an announcement of a presentation is classified as a Regulatory Filing (RNS) or a general announcement, as it does not contain the actual presentation content.
2022-10-11 English
Interim results for the six months to 30 June 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim results for the six months to 30 June 2022' and contains comprehensive unaudited condensed consolidated interim financial statements, including statements of financial position, loss and comprehensive loss, changes in equity, and cash flows. It provides detailed financial data and management commentary for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-27 English
The Ottawa Hospital pilots nasal disinfection
Regulatory Filings Classification · 98% confidence The document is a press release issued via the RNS Reach service, which is a non-regulatory distribution channel for corporate news. It details a business development update regarding a pilot program between Ondine Biomedical Inc. and The Ottawa Hospital. Since it does not fit into specific categories like financial reports, governance, or shareholder notifications, and is a general corporate announcement, it falls under the Regulatory Filings (RNS) category as the fallback for miscellaneous corporate news.
2022-09-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.